A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY AND VACCINE-LIKE VIRAL SHEDDING OF MEDI-534, AGAINST RESPIRATORY SYNCYTIAL VIRUS (RSV) AND PARAINFLUENZA VIRUS TYPE 3 (PIV3), IN HEALTHY 6 TO <24 MONTH-OLD CHILDREN AND IN 2 MONTH-OLD INFANTS: